Verastem, Inc. is an emerging biopharmaceutical firm dedicated to the discovery, development, and eventual commercialization of innovative therapies targeting various cancers. Central to its pipeline is VS-6766, an investigational compound designed as a potent dual inhibitor of rapidly accelerated fibrosarcoma (RAF) and mitogen-activated protein kinase (MEK). This unique "clamp" mechanism interferes with MEK kinase activity and prevents RAF from phosphorylating MEK, thereby disrupting a critical cancer pathway.